Follow The Filings

AIM AIM ImmunoTech

AIM ImmunoTech earnings company data as of 4:49 AM ET 10/23

Limited consensus data for this ticker (thin coverage or data-plan limits). Dates may be company-announced rather than sell-side consensus. Calendar and recent prints remain the primary lens when available.

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 16 Nov EPS — — —
Rev — — —

Insider trades

Open-market buys and sales by AIM's executives, directors and 10% owners in the last 12 months, from their Form 4s

All AIM insider trades
  • $19K bought by 1 insider
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Thomas K Equels CEO
    Buy
    $5,094 31,250 shares at $0.1600 +25% to stake
    Traded Oct 22 Filed Oct 23
  2. Thomas K Equels CEO
    Buy
    $4,992 24,000 shares at $0.2100 +23% to stake
    Traded Sep 17 Filed Sep 18
  3. Thomas K Equels CEO
    Buy
    $2,310 11,000 shares at $0.2100 +12% to stake
    Traded Sep 16 Filed Sep 17
  4. Thomas K Equels CEO
    Buy
    $4,862 22,000 shares at $0.2200 +32% to stake
    Traded Sep 15 Filed Sep 16
  5. Thomas K Equels CEO
    Buy
    $1,292 5,900 shares at $0.2200 +9.2% to stake
    Traded Sep 14 Filed Sep 15

Also filed in the last 12 months, not counted as buying or selling: 2 conversions and 1 stock grant.

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
DEF 14A
8-K 1.01,3.02,9.01
8-K 1.01,3.02,9.01
8-K 1.01,1.02,3.02,9.01
8-K 7.01,9.01
8-K 2.02,9.01
10-Q
8-K 1.01,5.08,9.01
8-K 1.02
8-K 5.07
DEF 14A
424B3
S-1
424B3
8-K 8.01,9.01
8-K 1.01,3.02,8.01,9.01
424B5
8-K 5.03,9.01
S-1
8-K 7.01,9.01
SCHEDULE 13G —
424B5
8-K 1.01,3.02,8.01,9.01
8-K 1.01,2.02,2.03,7.01,9.01
424B5

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.